Novartis announced updated results from the ELIANA
clinical trial of KymriahTM (tisagenlecleucel), formerly CTL019, in relapsed or refractory (r/r)
pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL) have been published in The New England Journal of Medicine (NEJM).
